Newsdesk

News releases of TVM Capital Life Science portfolio companies.

Proteon Therapeutics Announces Publication of Results from Phase 2 Study of PRT-201

-Data in Journal of Vascular Surgery Demonstrate Potential to Improve Function and Durability of Vascular Access Required for Hemodialysis- WALTHAM, Mass. – May 14, 2014 – Proteon Therapeutics Inc., a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases, today announced the online […]

TVM Life Science Ventures VII Announces Investment in PRCL Research Inc.

Montréal, Québec, May 12th, 2014 –TVM Life Science Ventures VII today announced the fund’s fourth investment, a co-investment with the Fonds de solidarité FTQ (the “Fonds”) – establishing PRCL Research Inc., a company based in Montréal, Québec. PRCL Research Inc. plans to develop, to proof-of-concept, a compound originally discovered by Synta Pharmaceuticals Inc. with the […]

invendo medical closes € 20M equity capital funding led by Xeraya Capital

Significant financing to accelerate industrialization and commercialization of invendo’s single-use colonoscope – Kissing, Germany – Garden City, NY — March 20, 2014 — invendo medical, manufacturer and distributor of a single-use and computer-assisted colonoscopy system, today announced the closing of a € 20.3 million ($ 28 million) financing round led by new investor Xeraya Capital […]

TVM Capital Life Science counts two successful biotech IPOs of portfolio in the U.S. market in the last two weeks – which brings the total to four IPOs within 10 months, raising $ 300 million

argos-therapeutics

Munich, Montreal,  February 19, 2014 — Biotech IPOs continue to roll on and it is an explicit pleasure for TVM Capital Life Science as an investor to be part of the now year-long biotech IPO boom on NASDAQ  which is one of the busiest IPO period in the history of U.S. biotech. Only a few […]

Concert Pharmaceuticals Announces Pricing of Initial Public Offering

LEXINGTON, Mass.–(BUSINESS WIRE)–Concert Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts. In addition, Concert has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at […]